Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
767.63 757.36 751.32 623.76 603.81 717.29 537.41 193.82 173.76 141.78
Receivables
158.59 134.12 124.16 116.25 117.42 71.39 43.67 35.75 27.74 16.03
Inventory
170.46 142.96 202.32 238.28 184.49 95.03 54.83 42.26 39.00 24.70
Total current assets
1,137.39 1,066.04 1,111.35 998.12 931.68 902.38 641.83 275.74 242.78 184.15
Property, Plant, Equpment (Net)
186.61 197.74 207.44 190.67 124.96 66.87 48.46 32.18 22.42 14.96
Goodwill and Intangible Assets (Total)
1,500.56 1,428.89 1,394.08 1,216.13 1,197.64 905.41 680.97 462.17 472.09 89.35
Long Term Assets (Tax, Deferred)
0.69 0.75 1.53 0.84 1.90 2.48 2.92 4.36 — —
Long-term assets (Other)
4.91 0.87 1.28 0.82 0.62 0.57 0.24 0.17 6.23 0.45
Total non-current assets
1,812.31 1,763.63 1,719.84 1,533.48 1,426.68 1,000.51 758.29 498.88 500.74 104.76
Total Assets
2,949.70 2,829.67 2,831.19 2,531.60 2,358.35 1,902.89 1,400.11 774.62 743.52 288.91
Accounts Payable
30.01 32.13 19.56 27.55 36.20 16.88 11.43 10.49 7.28 5.06
Accrued Expenses
79.21 62.42 57.31 71.12 75.50 53.09 33.33 15.87 17.93 16.01
Current Part of Debt
— — 69.45 284.62 255.26 243.74 4.00 103.49 — —
Other current liabilities
5.05 17.13 12.98 13.95 71.00 52.00 29.00 15.00 16.00 14.00
Total current liabilities
135.83 126.79 164.94 404.20 375.26 318.96 48.31 129.84 25.21 21.08
Long Term Debt (Total)
542.21 525.57 510.14 131.00 102.00 26.00 232.77 — 99.25 95.27
Long Term Tax Liability (Deferred)
22.50 22.78 39.32 23.00 33.48 27.03 29.94 25.09 25.17 2.10
Non-current Liabilities (Other)
16.86 36.24 25.35 62.32 97.05 1.32 2.33 4.13 2.34 1.70
Total non-current liabilities
707.74 730.16 701.40 216.70 233.03 54.78 292.03 29.21 126.76 99.07
Total liabilities
843.57 856.95 866.34 620.90 608.29 373.74 340.35 159.05 151.97 120.15
Additional Paid In Capital
1,651.85 1,617.34 1,569.23 1,547.27 1,572.34 1,460.75 1,068.43 642.59 628.98 242.04
Common Stock (Net)
0.56 0.56 0.56 0.56 0.55 0.55 0.52 0.44 0.44 0.34
Retained Earnings
456.25 407.35 432.87 397.27 194.06 65.77 5.84 (15.57) (31.51) (59.86)
Common Equity (Total)
2,106.13 1,972.72 1,964.85 1,910.70 1,750.07 1,529.15 1,059.77 615.57 591.55 168.76
Shareholders Equity (Total)
2,106.13 1,972.72 1,964.85 1,910.70 1,750.07 1,529.15 1,059.77 615.57 591.55 168.76
Shareholders Equity and Liabilities (Total)
2,949.70 2,829.67 2,831.19 2,531.60 2,358.35 1,902.89 1,400.11 774.62 743.52 288.91
Shares (Common)
56.33 56.09 55.77 55.56 55.32 54.76 52.08 43.92 43.59 33.84
Shareholders Equity (Tangible)
605.57 543.83 570.77 694.57 552.43 623.74 378.80 153.40 119.46 79.41
Net Debt
(225.41) (231.79) (171.73) (208.14) (246.56) (447.55) (300.64) (90.33) (74.51) (46.51)
Total Debt
542.21 525.57 579.60 415.62 357.26 269.74 236.77 103.49 99.25 95.27

Fold the line items

In millions of $ except per-share values · columns are period end dates